Corbus Pharmaceuticals Holdings Inc CRBP 深 沪
等待开盘 11-12 09:30:00 美东时间
4.00
+0.070
+1.78%
华盛通- 最 高4.20
- 今 开4.04
- 成交量 67.27万股
- 最 低 3.80
- 昨 收 3.93
- 总市值 7736.52万
- 52周最高 12.8808
- 市盈率 静 --
- 换手率 3.48%
- 52周最低 2.81
- 委 比 86.72%
- 总股本 1934.13万
- 历史最高 323.40
- 量 比 0.57
- 振 幅 10.18%
- 历史最低 2.11
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel等多家大行上调CoreWeave目标价；杰富瑞首予康宁"买入"评级
今日重点评级关注：韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从42美元升至44美元；HC Wainwright & Co.：维持WhiteFiber"买入"评级，目标价从34美元升至36美元
48分钟前
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
11-11 22:10
Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over losses of $(1.90) per share from the same period last year.
11-10 21:03
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported key milestones in Q3 2026, including initiating dosing in the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer and announcing positive topline data for CRB-913 in obesity, showing a 5% weight loss at 12 weeks with favorable safety. The company also appointed a new Chief Medical Officer and reported a net loss of $37.8 million, with $115.3 million in cash on hand.
11-10 13:00
Corbus Pharmaceuticals Holdings Inc.收涨14.66%，成交额444.4万美元
11月10日，Corbus Pharmaceuticals Holdings Inc.（CRBP）收涨14.66%，报3.52美元，成交额444.4万美元，市值...
11-10 08:16
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
Corbus Pharmaceuticals Holdings, Inc. announced that its CEO, Yuval Cohen, Ph.D., will present at three conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026; the Jefferies Global Healthcare Conference on November 18, 2026; and the 9th Annual Evercore Healthcare Conference on December 1, 2026. Each event will include presentations, fireside chats, and one-on-one investor meetings. Investors i...
11-05 13:00
Corbus Pharmaceuticals Holdings Inc.收跌7.23%，成交额267.88万美元
11月3日，Corbus Pharmaceuticals Holdings Inc.（CRBP）收跌7.23%，报3.92美元，成交额267.88万美元，市值...
11-03 08:09
Corbus Pharmaceuticals Holdings Inc.收跌1.94%，成交额149.78万美元
10月24日，Corbus Pharmaceuticals Holdings Inc.（CRBP）收跌1.94%，报4.05美元，成交额149.78万美元，市值...
10-24 07:12
Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at Obesity Week® 2026, taking place from Novembe...
10-22 20:03
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Corbus Pharmaceuticals will present late-breaking data from the CRB-913 Canyon-1 Phase 1B study at Obesity Week 2026 in National Harbor, MD. The presentation, titled "Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 Study," will be delivered by Harold Bays, M.D., on November 15, 2026, at 2:30 p.m. ET in Exhibit Hall BCD. Corbus is a clinical-stage company developing innovative therapies for oncology and obesity, with CRB-913 bei...
10-22 12:00
